Revvity Bundle
Who owns Revvity today?
When PerkinElmer spun off its analytical instruments business and rebranded the life‑sciences unit as Revvity in May 2023, ownership shifted to public markets and large institutional holders. The company now focuses on genomics, proteomics, imaging and diagnostics from Waltham, MA.
Public shareholders dominate Revvity ownership, led by major US institutions and index funds; insiders and the board hold smaller stakes while buybacks and capital allocation shape voting power and returns. See Revvity Porter's Five Forces Analysis for strategic context.
Who Founded Revvity?
Founders and Early Ownership of Revvity trace back to PerkinElmer’s origins rather than a startup cap table; Revvity is the carved‑out successor to PerkinElmer’s life‑sciences and diagnostics units after the 2022–2023 reorganization.
Historic founders
PerkinElmer was founded in 1937 by Richard Scott Perkin and Charles Elmer; early ownership rested with the founders and initial employees.
Public transition
PerkinElmer completed an IPO in 1947, broadening ownership to the public and institutional investors.
Acquisition-driven dilution
Decades of acquisitions and share issuances diluted any founder‑family concentration into a widely held public float.
No startup equity
Revvity has no founder equity splits, vesting schedules, or buy–sell clauses because it formed via corporate reorganization, not venture formation.
Early backers
Early backers were public‑market investors post‑IPO rather than angel investors or venture capital firms.
Founder rights
There are no disclosed founder special rights or golden shares that carried into Revvity after the carve‑out.
Revvity ownership today is reflected through public filings and institutional holders inherited from PerkinElmer’s public float; see SEC filings and the company investor relations for shareholder lists and majority owner details.
Key points on founders and early ownership
Founders and early ownership timeline and effects on present Revvity ownership structure
- Founded as PerkinElmer in 1937 by Richard Scott Perkin and Charles Elmer; IPO in 1947
- Ownership transitioned from founders to public shareholders after the IPO and decades of capital actions
- Revvity emerged from a 2022–2023 carve‑out and corporate name change, not a new equity round
- Largest current shareholders are institutional investors listed in SEC filings; no founder‑held controlling stake carried into Revvity
For context on market positioning and customer segments following the carve‑out, see Target Market of Revvity
Revvity SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Revvity’s Ownership Changed Over Time?
Key events reshaping Revvity ownership include PerkinElmer’s decade of life‑sciences acquisitions (2011–2021), the divestiture of Analytical & Enterprise Solutions to New Mountain Capital (announced August 2022, closed March 2023), and the May 2023 rebrand and NYSE ticker change to RVTY, which shifted the shareholder mix toward healthcare specialists and index funds.
| Period | Event | Ownership Impact |
|---|---|---|
| 2011–2021 | PerkinElmer added Caliper Life Sciences (2011), ViaCord earlier, and reagent/platform tuck‑ins | Revenue mix grew in what became Revvity; ownership remained widely held among institutions |
| 2022–Mar 2023 | AES sold to New Mountain Capital (~$2.45 billion enterprise value) | Company refocused on Life Sciences & Diagnostics; generalist industrial investors rotated out |
| May 2023–2025 | Rebrand to Revvity, NYSE ticker RVTY; standalone public company | Institutional ownership > 85%; passive and healthcare specialists became dominant |
The standalone market cap ranged roughly between $8 billion and $12 billion through 2024–mid‑2025; insider holdings have been low single‑digits and no controlling or parent company exists. For background on corporate origins see Brief History of Revvity.
Major shareholders and ownership posture
Institutional investors and index complexes hold the bulk of Revvity shares following the 2023 separation; ownership is diversified with a small insider stake.
- The Vanguard Group — around ~10% of shares outstanding in 2024–2025
- BlackRock, Inc. — commonly ~7–9%
- State Street Global Advisors — typically ~4–6%
- Collective positions by Capital Group, Wellington, Fidelity, T. Rowe Price and Northern Trust amount to a meaningful double‑digit percentage
Revvity PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Revvity’s Board?
As of 2024–2025 the Revvity board comprises a majority of independent directors with expertise across diagnostics, biopharma tools and global operations; the chair and CEO roles are separated and key committees (audit, compensation, nominating/governance) are fully independent.
| Role | Typical Background | Independence |
|---|---|---|
| Chief Executive Officer | Company executive leadership; operational responsibility | No |
| Independent Chair / Lead Independent Director | Former CEO/C-suite of medtech or biopharma tools firms | Yes |
| Audit Committee Members | Finance, accounting, global compliance experience | Yes |
| Compensation Committee Members | HR, executive compensation design, public company board experience | Yes |
| Nominating & Governance Members | Corporate governance, regulatory and international operations | Yes |
The board typically includes the CEO plus a slate of independent members drawn from major medtech/biopharma or scientific tools firms; there are no publicly disclosed directors appointed by a controlling investor, and director composition reflects broad institutional shareholder expectations rather than designated fund seats.
Voting Structure and Shareholder Influence
Revvity uses a one-share-one-vote common stock structure with no dual-class shares or founder super-voting rights; voting power is proportional to ownership and large institutional holders exert outsized influence via proxy voting.
- Voting: one-share–one-vote; no dual-class or golden shares
- Major influencers: passive index funds and large active managers (BlackRock, Vanguard, State Street commonly top holders in comparable public medtech firms)
- Recent governance outcomes: say-on-pay and director elections passed with strong majorities in recent proxy seasons
- Engagement priorities: capital allocation (buybacks vs. M&A), R&D productivity, margin improvement
Institutional ownership is the dominant force in Revvity ownership dynamics—SEC filings and 13F reports (2024–2025) show typical top institutional holders in similar companies hold between 5% and 15% each, with combined passive funds often exceeding 20–30%; for detailed context see Mission, Vision & Core Values of Revvity.
Revvity Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Revvity’s Ownership Landscape?
From 2023 through mid-2025 Revvity ownership shows portfolio sharpening, buybacks and growing passive concentration; management prioritized bolt-on M&A in reagents and genomic workflows while executing authorized repurchases that trimmed shares by a low-single-digit percent.
| Ownership Category | Typical 2023–2025 Range | Notable Notes |
|---|---|---|
| Top passive institutions | 17–20% combined (Vanguard + BlackRock) | Indexation drove concentrated passive voting influence |
| Other passive / State Street | Mid-single-digit percent | Reinforces governance outcomes aligned with large-cap norms |
| Specialized healthcare funds | High-single-digit to low-double-digit percent collectively | Active sector-focused ownership, targeted engagement |
Industry trends show life science tools ownership tilting to larger passive stakes and sector specialists; activism in the sector rose but Revvity had no public activist-driven board changes as of mid-2025, and filings indicate continued public ownership without moves toward privatization or dual-class structure.
Capital deployment
Management emphasized tuck-in acquisitions funded by operating cash flow and modest share repurchases; 2023–2024 buybacks reduced shares by a low-single-digit percent cumulatively.
Institutional concentration
Vanguard and BlackRock together often held roughly 17–20% of shares, with State Street and other passive vehicles adding mid-single-digit percentages.
Governance implications
Passive indexing increased voting alignment with market norms; no evidence as of 2025 of dual-class adoption, privatization bids, or founder/family control in Revvity ownership structure.
Analyst outlook
Analysts expect continued tuck-in M&A and sustained buybacks depending on valuation; SEC filings and management commentary point to steady public ownership and ongoing engagement by top institutional holders.
For additional context on competitive positioning and ownership impacts see Competitors Landscape of Revvity
Revvity Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Revvity Company?
- What is Competitive Landscape of Revvity Company?
- What is Growth Strategy and Future Prospects of Revvity Company?
- How Does Revvity Company Work?
- What is Sales and Marketing Strategy of Revvity Company?
- What are Mission Vision & Core Values of Revvity Company?
- What is Customer Demographics and Target Market of Revvity Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.